# US 2026/0083729 A1 · Methods for treatment of bone marrow failure and related conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083729 A1
- Document ID: US20260083729A1
- Status: Published application
- Kind: A1
- Application number: 19/137,870
- Filed: 2023-12-15
- Published: 2026-03-26
- Earliest claimed: 2022-12-23
- Assignees: Imago Biosciences, Inc.
- Applicants: Imago Biosciences, Inc.
- Inventors: Maria Kleppe; Hugh Y. Rienhoff, JR.; Jennifer Dias
- Web page: https://patentgrep.com/patent/US20260083729A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/415: 1,2-Diazoles
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods for increasing the numbers of hematopoietic stem cells (HSCs) in a patient in need thereof, for treating a condition characterized by reduced numbers of hematopoietic stem cells (HSCs), such as bone marrow failure (BMF) or a BMF syndrome, in a patient in need thereof, for enhancing recovery from or improving tolerance of a near-ablative cancer therapy, and/or for reducing the damage to, or accelerating the recovery of, the hematopoietic compartment after a physical insult thereto in a patient in need thereof, comprising administering in vivo or treating cells ex vivo with an LSD1 inhibitor.

## Claims

### Claim 1

A method of increasing the numbers of hematopoietic stem cells in a patient in need thereof comprising i) administering an LSD1 inhibitor to the patient in an amount and/or for a period of time sufficient to result in an in vivo expansion of a population of hematopoietic stem cells; or ii) contacting hematopoietic stem cells harvested from a patient or a suitable donor with an LSD1 inhibitor ex vivo, in an amount and/or for a period of time sufficient to result in an expansion of a population of hematopoietic stem cells, then administering to the patient a therapeutically effective amount of the expanded population of hematopoietic stem cells.

### Claim 2 (depends on 1)

The method of claim 1 wherein the patient has a condition characterized by reduced numbers of hematopoietic stem cells.

### Claim 3

A method of treating a condition characterized by reduced numbers of hematopoietic stem cells in a patient in need thereof, comprising i) administering an LSD1 inhibitor to the patient in an amount and/or for a period of time sufficient to result in an in vivo expansion of a population of hematopoietic stem cells; or ii) contacting hematopoietic stem cells harvested from a patient or a suitable donor with an LSD1 inhibitor ex vivo, in an amount and/or for a period of time sufficient to result in an expansion of a population of hematopoietic stem cells, then administering to the patient a therapeutically effective amount of the expanded population of hematopoietic stem cells.

### Claim 4

A method of enhancing recovery from a near-ablative cancer therapy comprising, subsequent to such therapy, i) administering an LSD1 inhibitor to the patient in an amount and/or for a period of time sufficient to result in an in vivo expansion of a population of hematopoietic stem cells; or ii) contacting hematopoietic stem cells harvested from a patient or a suitable donor with an LSD1 inhibitor ex vivo, in an amount and/or for a period of time sufficient to result in an expansion of a population of hematopoietic stem cells, then administering to the patient a therapeutically effective amount of the expanded population of hematopoietic stem cells.

### Claim 5

A method of improving tolerance of a near-ablative cancer therapy comprising, prior to such therapy, i) administering an LSD1 inhibitor to the patient in an amount and/or for a period of time sufficient to result in an in vivo expansion of a population of hematopoietic stem cells; or ii) contacting hematopoietic stem cells harvested from a patient or a suitable donor with an LSD1 inhibitor ex vivo, in an amount and/or for a period of time sufficient to result in an expansion of a population of hematopoietic stem cells, then administering to the patient a therapeutically effective amount of the expanded population of hematopoietic stem cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the near-ablative cancer therapy is administered after a period of time after administration of the LSD1 inhibitor sufficient for cells to re-enter the quiescent phase.

### Claim 7 (depends on 6)

The method of claim 6, wherein the period of time sufficient for cells to enter the quiescent phase is between about one and about two weeks.

### Claim 8

The method of 4, wherein the near-ablative cancer therapy is chosen from therapeutic irradiation of cancer cells and cytotoxic chemotherapy of cancer cells.

### Claim 9

A method of reducing the damage to, or accelerating the recovery of, the hematopoietic compartment after a physical insult thereto in a patient in need thereof, comprising i) administering an LSD1 inhibitor to the patient in an amount and/or for a period of time sufficient to result in an in vivo expansion of a population of hematopoietic stem cells; or ii) contacting hematopoietic stem cells harvested from a patient or a suitable donor with an LSD1 inhibitor ex vivo, in an amount and/or for a period of time sufficient to result in an expansion of a population of hematopoietic stem cells, then administering to the patient a therapeutically effective amount of the expanded population of hematopoietic stem cells.

### Claim 10 (depends on 7)

The method of claim 7, wherein the physical insult is a result of irradiation or chemical toxicity.

### Claim 11 (depends on 1)

The method of claim 1, wherein administration of the LSD1 inhibitor results in proliferation of the hematopoietic stem cells in the bone marrow.

### Claim 12 (depends on 1)

The method of claim 1, wherein administration of the LSD1 inhibitor reduces a proportion of quiescent cells in the hematopoietic stem cell population.

### Claim 13 (depends on 1)

The method of claim 1, wherein administration of the LSD1 inhibitor results in the hematopoietic stem cells entering the cell division cycle, thereby increasing the number of hematopoietic stem cells in the bone marrow and in the peripheral circulation.

### Claim at position 14

14-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the numbers of hematopoietic stem cells are reduced by 50% prior to administration of the LSD1 inhibitor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the reduced numbers of hematopoietic stem cells classify the patient as having bone marrow failure.

### Claim 22 (depends on 21)

The method of claim 21, wherein reduced numbers of peripheral blood cells, i.e., cytopenia, anemia, thrombocytopenia, lymphopenia, or neutropenia classify the patient as having bone marrow failure.

### Claim 23 (depends on 1)

The method of claim 1, wherein the condition characterized by reduced numbers of hematopoietic stem cells is chosen from a bone marrow failure syndrome, a myeloproliferative neoplasm, and a myelodysplastic syndrome.

### Claim at position 19

24-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein the condition characterized by reduced numbers of hematopoietic stem cells is an autoimmune condition causing aplastic anemia.

### Claim 35 (depends on 1)

The method of claim 1, wherein the condition characterized by reduced numbers of hematopoietic stem cells is the result of a mutation in a lineage cell.

### Claim 36 (depends on 35)

The method of claim 35, wherein the lineage cell is a progenitor cell of the erythroid lineage, megakaryocytic lineage, or granulo-monocytic lineage.

### Claim 37 (depends on 35)

The method of claim 35, wherein the lineage cell is chosen from common myeloid progenitor, erythroid progenitor cell, megakaryocytic progenitor cell, a granulocyte-monocyte progenitor, or a megakaryocytic-erythroid progenitor cell.

### Claim 38 (depends on 35)

The method of claim 35, wherein the mutation in a lineage cell leads to altered numbers of, malformations in, or impaired function of one or more cells chosen from granulocytes, megakaryocytes, erythrocytes, neutrophils, basophils, eosinophils, monocytes, and dendritic cells.

### Claim at position 25

39-49. (canceled)

### Claim 50 (depends on 1)

The method of claim 1, wherein the dose of the LSD1 inhibitor is from about 0.25 mg/kg to about 7 mg/kg.

### Claim 51 (depends on 1)

The method of claim 1, wherein the dose of the LSD1 inhibitor is from about 10 mg to about 700 mg.

### Claim at position 28

52-66. (canceled)

### Claim 67 (depends on 1)

The method of claim 1, wherein the LSD1 inhibitor is
or a polymorph or solvate thereof.

### Claim 68

(canceled)
